博雅生物：关于全资子公司获得《药品补充申请批准通知书》的公告

Group 1 - The core announcement is that Boya Bio has received approval from the National Medical Products Administration for three specifications of intravenous human immunoglobulin (pH4) [1] - The approval was granted to Green Cross (China) Biological Products Co., Ltd., a wholly-owned subsidiary of Green Cross Hong Kong Holdings Limited, which is itself a wholly-owned subsidiary of Boya Bio [1] - The approval notification includes three specific notification numbers: 2026B00463, 2026B00465, and 2026B00466 [1]